Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK2637-008 | |||
| 2009_608 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | MK2637 120 mg |
|
| 2 | Experimental | MK2637 50 mg |
|
| 3 | Placebo Comparator | Placebo |
|
| 4 | Active Comparator | Dextromethorphan 220 mg |
|
| 5 | Active Comparator | Dextromethorphan 110 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK2637 | Drug | Single dose of 120 mg MK2637 capsules in one of five treatment periods. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Increase in Motor Evoked Potential (MEP) after dosing with dextromethorphan compared to placebo | 5 Hours after initial dosing | |
| Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG after dosing with dextromethorphan compared to placebo | 4 Hours after initial dosing |
| Measure | Description | Time Frame |
|---|---|---|
| Increase in amplitude in the theta frequency band (4-8 Hz) of resting qEEG after dosing with MK2637 compared to placebo | 6.5 hours after initial dosing | |
| Change in Motor Evoked Potential (MEP) after dosing with MK2637 as compared to placebo | 5 hours after initial dosing |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: MK2637 |
| Drug |
Single dose of 50 mg MK2637 capsules in one of five treatment periods. |
|
| Comparator: Placebo | Drug | Single dose of placebo only in one of five treatment periods. |
|
| Comparator: Dextromethorphan | Drug | Single dose of 220 mg dextromethorphan capsules in one of five treatment periods. |
|
| Comparator: Dextromethorphan | Drug | Single dose of 110 mg dextromethorphan capsules in one of five treatment periods. |
|
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided